Physician profile
Alan Diaz
NPI 1104936335
$13,197.78
in general payments reported to CMS, 2019-2025
45 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,999 · 2020: $953 · 2021: $2,186 · 2022: $2,140 · 2023: $1,968 · 2024: $820 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,792 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,792.45 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,178.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,025.25 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $758.31 | 2019-2024 | Trulance |
| Teva Pharmaceuticals USA, INC. | $741.48 | 2019-2024 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $578.32 | 2024-2025 | Cobenfy |
| Amgen INC. | $508.86 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $495.04 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $474.34 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $364.04 | 2019-2024 | |
| Allergan, INC. | $292.46 | 2019-2020 | |
| Abbvie INC. | $268.55 | 2021-2025 | Qulipta, Ubrelvy, Linzess |
| Esperion Therapeutics, INC. | $207.89 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $191.69 | 2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $174.93 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $164.15 | 2022-2024 | Linzess |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.